Azole heteroresistance in Cryptococcus neoformans: emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatment
about
Fluconazole alters the polysaccharide capsule of Cryptococcus gattii and leads to distinct behaviors in murine CryptococcosisA Population Genomics Approach to Assessing the Genetic Basis of Within-Host Microevolution Underlying Recurrent Cryptococcal Meningitis Infection.Multilocus sequence typing of serially collected isolates of Cryptococcus from HIV-infected patients in South Africa.Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis.Rapid mechanisms for generating genome diversity: whole ploidy shifts, aneuploidy, and loss of heterozygosityCryptococcus neoformans Yap1 is required for normal fluconazole and oxidative stress resistanceSilencing is noisy: population and cell level noise in telomere-adjacent genes is dependent on telomere position and sir2.Cryptococcosis diagnosis and treatment: What do we know nowRising to the challenge of multiple Cryptococcus species and the diseases they cause.Polyploid titan cells produce haploid and aneuploid progeny to promote stress adaptationFluconazole-Induced Ploidy Change in Cryptococcus neoformans Results from the Uncoupling of Cell Growth and Nuclear Division.Cryptococcus: from environmental saprophyte to global pathogen.Microevolution of Serial Clinical Isolates of Cryptococcus neoformans var. grubii and C. gattii.Mechanisms of Antifungal Drug Resistance.Cryptococcal therapies and drug targets: the old, the new and the promising.The fungal resistome: a risk and an opportunity for the development of novel antifungal therapies.Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.Ploidy dynamics and evolvability in fungiHeteroresistance and fungi.Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.Fluconazole Non-susceptible Cryptococcus neoformans, Relapsing/Refractory Cryptococcosis and Long-term Use of Liposomal Amphotericin B in an AIDS Patient.In vivo development of fluconazole resistance in serial Cryptococcus gattii isolates from a cat.Update on Antifungal Drug Resistance.Glucosamine stimulates pheromone-independent dimorphic transition in Cryptococcus neoformans by promoting Crz1 nuclear translocation.Large-Scale Chromosomal Changes and Associated Fitness Consequences in Pathogenic Fungi.The Influence of Genetic Stability on Aspergillus fumigatus Virulence and Azole Resistance.Discovery of an Octahedral Silicon Complex as a Potent Antifungal Agent.Peeling the onion: the outer layers of Cryptococcus neoformans.MLST reveals a clonal population structure for Cryptococcus neoformans molecular type VNI isolates from clinical sources in Amazonas, Northern-Brazil.Colony and Single Cell Level Analysis of the Heterogeneous Response of Cryptococcus neoformans to Fluconazole.Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.
P2860
Q28544939-51A6D60C-E68B-48AC-8857-2BC619530F1CQ30844823-AB253BFD-6E47-407A-B7DF-E3B4C2E29BFAQ33703545-A6628093-7397-4195-A7F2-5BF5AC6EA446Q33790656-91D9D8A4-1B46-42B7-AD1D-6245A728E11AQ34355333-F4AC1F0E-60A7-4E26-AC02-039B9DF96635Q34943653-1C1D9C21-1805-4D85-B283-D0121E420E8BQ35212268-DB2DA583-0047-42B0-9C3D-25FD2D213CE2Q35395169-C479C99D-FF5D-4C3E-9F3A-F0A5280E6633Q35706177-305B1C7F-C137-442B-AC8E-0109CDD9EB10Q36205846-72A4B938-77FD-4100-BA28-47D611A57963Q36409929-89343149-6122-49A3-A796-064D362AFAFEQ37250158-B2406E2D-07A2-4AE0-8E96-DA0A68F88A0CQ37685585-21A47084-80A4-47AC-B2E7-12A866DDDA27Q38266675-23E034A9-D2C7-42B9-8F10-71F6D1403B98Q38779568-D20B94E2-C1F9-497A-9D23-1C7C433FCF67Q38835045-2460ECE3-5662-4C4F-8521-0286A714C8CCQ38852907-F81A5D17-6B32-49CE-86CE-A67FDE5BCF62Q39084067-736B9590-E93F-4EE3-B3D7-BAE10C071942Q39404146-BBB508AA-3FED-4E2E-954A-E42092377711Q40100243-8BA50527-80E9-4C0E-B8FF-17468EE28176Q40155503-902A3F2B-A8B9-432F-8A83-20B4E687E1F1Q40851096-AE46754E-1E32-4CF2-868B-76C10FEF4F52Q41135029-B07C429E-D6D7-455C-9610-25F03D700AF4Q41229705-52643F70-CCB2-4E78-8DBC-CBCD366A9564Q43144415-ED6367D9-B767-4153-94B5-46764DB3DF1DQ48279550-B02D727C-E6A3-4FF0-9C56-D4E0D22ACD02Q52677950-15A07E30-A72D-41D7-8918-4582E7D5B0F2Q55056045-92A3E717-6578-4D20-85C9-D6E7922C9741Q55214082-1FFD88A9-BB59-42FC-AD12-68CD3927132BQ55420832-17FFB8EC-B511-49DC-909A-4A6977FBF0CFQ55511181-59E6B92F-F5F4-46EB-AB5E-DDDD006DAF6A
P2860
Azole heteroresistance in Cryptococcus neoformans: emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatment
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Azole heteroresistance in Cryp ...... n during fluconazole treatment
@en
Azole heteroresistance in Cryp ...... during fluconazole treatment.
@nl
type
label
Azole heteroresistance in Cryp ...... n during fluconazole treatment
@en
Azole heteroresistance in Cryp ...... during fluconazole treatment.
@nl
prefLabel
Azole heteroresistance in Cryp ...... n during fluconazole treatment
@en
Azole heteroresistance in Cryp ...... during fluconazole treatment.
@nl
P2093
P2860
P356
P1476
Azole heteroresistance in Cryp ...... n during fluconazole treatment
@en
P2093
Edward Sionov
Kyung J Kwon-Chung
Yun C Chang
P2860
P304
P356
10.1128/AAC.00694-13
P407
P577
2013-07-08T00:00:00Z